Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,633,852
  • Shares Outstanding, K 90,820
  • Annual Sales, $ 753,200 K
  • Annual Income, $ -263,300 K
  • EBIT $ -144 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.93
  • Price/Sales 2.65
  • Price/Cash Flow N/A
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 69.40% ( -8.58%)
  • Historical Volatility 67.48%
  • IV Percentile 95%
  • IV Rank 80.64%
  • IV High 83.16% on 03/25/24
  • IV Low 12.10% on 06/03/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 198
  • Volume Avg (30-Day) 183
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 3,523
  • Open Int (30-Day) 2,888

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 7
  • High Estimate -0.02
  • Low Estimate -0.11
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +58.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.86 +5.75%
on 11/01/24
26.60 -32.97%
on 10/07/24
-8.64 (-32.64%)
since 10/04/24
3-Month
16.86 +5.75%
on 11/01/24
29.30 -39.15%
on 09/18/24
-8.82 (-33.10%)
since 08/02/24
52-Week
15.99 +11.47%
on 11/10/23
29.30 -39.15%
on 09/18/24
+0.81 (+4.76%)
since 11/03/23

Most Recent Stories

More News
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

MYGN : 17.83 (-0.89%)
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

MYGN : 17.83 (-0.89%)
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

MYGN : 17.83 (-0.89%)
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

MYGN : 17.83 (-0.89%)
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

MYGN : 17.83 (-0.89%)
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

MYGN : 17.83 (-0.89%)
Myriad: Q2 Earnings Snapshot

Myriad: Q2 Earnings Snapshot

MYGN : 17.83 (-0.89%)
Myriad: Q1 Earnings Snapshot

Myriad: Q1 Earnings Snapshot

MYGN : 17.83 (-0.89%)
Myriad: Q4 Earnings Snapshot

Myriad: Q4 Earnings Snapshot

MYGN : 17.83 (-0.89%)
Myriad: Q3 Earnings Snapshot

Myriad: Q3 Earnings Snapshot

MYGN : 17.83 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 19.68
2nd Resistance Point 18.92
1st Resistance Point 18.38
Last Price 17.83
1st Support Level 17.08
2nd Support Level 16.32
3rd Support Level 15.78

See More

52-Week High 29.30
Fibonacci 61.8% 24.22
Fibonacci 50% 22.65
Fibonacci 38.2% 21.08
Last Price 17.83
52-Week Low 15.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar